Henggliflozin
Phase 3Small molecule
Henggliflozin is one of 36 small molecule programs targeting Heart Failure Preserved Ejection Fraction. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
171 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Henggliflozin
XXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 3
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Routine Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes1 trial
Heart Failure Preserved Ejection Fraction1 trial
Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF
Not yet recruiting·TThe First Affiliated Hospital of Air Force Medicial University·Preclinical·NCT07687212·162 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Henggliflozin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details